TrialClinical and experimental nephrology2018

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Takashi Wada et al.PubMed ↗Publisher ↗

No numbers read from the abstract.